retatrutide nonalcoholic fatty liver disease nash trial Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom retatrutide nonalcoholic fatty liver disease

These hormones naturally influence how the body processes food, stores fat, and burns calories

Medicare GLP-1 Bridge is a short-term CMS demonstration which runs from July 1, 2026 to December 31, 2027

On the other hand data from the Diabetes Prevention Program study of 3234 pre-diabetic subjects over an average of 2.8 years who were randomized to receive placebo, metformin (850 mg bid), or lifestyle intervention, indicated that although both metformin and lifestyle changes were effective in reducing the risk of developing diabetes, lifestyle intervention was more effective (7)

Product Name: Retatrutide

Wegovy recently also gained approval for the treatment of fatty liver disease (technically called metabolic dysfunction-associated steatohepatitis or MASH) in adults with moderate to advanced liver fibrosis

Kaufman believes that by reducing systemic inflammation, the GLP-1 agonists are getting at one of the root causes of these diseases